Compare Moderna, Inc. (MRNA) vs Solaredge Technologies Inc (SEDG) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.

SolarEdge Technologies (SEDG) trades at $32.47, down 2.08% amid bearish technical signals and ongoing financial challenges. The company reported a net loss of $405 million in 2025 with negative profit margins, though revenue showed some recovery to $1.18 billion. Recent news highlights multiple law firm investigations into investor claims while the company pursues AI data center expansion opportunities.

The outlook remains challenging with significant execution risks and negative profitability, though analyst consensus suggests modest upside potential to the $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures in solar markets, and the company's ability to achieve its ambitious 2029 revenue target of $2.4 billion.